Efficacy and safety of eptinezumab for migraine prevention in patients with 2-4 prior preventive treatment failures

被引：0
|
作者：
Ashina, M. [1 ]
Lanteri-Minet, M. [2 ]
Pozo-Rosich, P. [3 ,4 ,5 ]
Ettrup, A. [6 ]
Boyle, L. [7 ]
Christoffersen, C. [6 ]
Josiassen, M. [6 ]
Phul, R. [6 ]
Sperling, B. [8 ]
机构：
[1] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, Glostrup, Denmark
[2] Hosp Pasteur, Univ Teaching Hosp, Nice, Provence Alpes, France
[3] Vall dHebron Univ Hosp, Neurol Dept, Headache Unit, Barcelona, Spain
[4] Inst Res, Barcelona, Spain
[5] Univ Autonoma Barcelona, Barcelona, Spain
[6] H Lundbeck & Co AS, Copenhagen, Denmark
[7] Lundbeck LLC, Deerfield, IL USA
[8] H Lundbeck & Co AS, Copenhagen, Denmark
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-164
引用
收藏
页码：141 / 142
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2-4 Prior Preventive Treatment Failures
    Ashina, M.
    Lanteri-Minet, M.
    Pozo-Rosich, P.
    Ettrup, A.
    Christoffersen, C. L.
    Josiassen, M. K.
    Phul, R.
    Sperling, B.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [2] Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2-4 Prior Preventive Treatment Failures
    Ashina, M.
    Lanteri-Minet, M.
    Pozo-Rosich, P.
    Ettrup, A.
    Christoffersen, C.
    Josiassen, M.
    Phul, R.
    Sperling, B.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 418 - 418
  • [3] Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
    Ashina, M.
    Lanteri-Minet, M.
    Pozo-Rosich, P.
    Ettrup, A.
    Christoffersen, C.
    Josiassen, M.
    Phul, R.
    Sperling, B.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 192 - 192
  • [4] Eptinezumab for migraine prevention in patients with 2-4 prior treatment failures: DELIVER subpopulation analysis
    Ashina, M.
    Lanteri-Minet, M.
    Pozo-Rosich, P.
    Ettrup, A.
    Boyle, L.
    Christoffersen, C.
    Josiassen, M.
    Phul, R.
    Sperling, B.
    [J]. HEADACHE, 2022, 62 : 145 - 145
  • [5] Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
    Ashina, M.
    Lanteri-Minet, M.
    Pozo-Rosich, P.
    Ettrup, A.
    Christoffersen, C. L.
    Josiassen, M. K.
    Phul, R.
    Sperling, B.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Long-term safety and effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Ashina, Messoud
    Tepper, Stewart J.
    Gendolla, Astrid
    Sperling, Bjorn
    Ettrup, Anders
    Josiassen, Mette Krog
    Starling, Amaal J.
    [J]. CEPHALALGIA, 2023, 43 (1supp) : 45 - 45
  • [7] Long-term safety and effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Ashina, M.
    Tepper, S. J.
    Gendolla, A.
    Sperling, B.
    Ettrup, A.
    Josiassen, M. K.
    Starling, A. J.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [8] Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study
    Ashina, Messoud
    Lanteri-Minet, Michel
    Ettrup, Anders
    Christoffersen, Cecilie Laurberg
    Josiassen, Mette Krog
    Phul, Ravinder
    Sperling, Bjorn
    Pozo-Rosich, Patricia
    [J]. CEPHALALGIA, 2023, 43 (05)
  • [9] Long-term effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Ashina, M.
    Tepper, S.
    Gendolla, A.
    Sperling, B.
    Ettrup, A.
    Josiassen, M.
    Starling, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 372 - 372
  • [10] Long-term effectiveness of eptinezumab in patients with prior preventive migraine treatment failures
    Starling, A.
    Ashina, M.
    Tepper, S.
    Gendolla, A.
    Sperling, B.
    Ettrup, A.
    Josiassen, M.
    [J]. HEADACHE, 2023, 63 : 144 - 145
12345